Bumetanide is a loop diuretic that inhibits the Na+-K+-2Cl- cotransporter 1 (NKCC1), a chloride importer expressed throughout the central nervous system. By reducing intracellular chloride, bumetanide restores the inhibitory function of GABA_A receptors in mature neurons, effectively reducing neuronal hyperexcitability. This mechanism has led to exploration of bumetanide as a repurposed therapy for Alzheimer's disease, where network hyperexcitability and epileptiform activity are increasingly recognized as key features.
Mechanism of Action
NKCC1 and Neuronal Excitation
NKCC1 (encoded by [SLC12A2](/genes/slc12a2)) imports Na⁺, K⁺, and Cl⁻ into neurons, maintaining elevated intracellular chloride levels. In mature neurons, this prevents GABA_A receptor activation from hyperpolarizing the cell, as the chloride reversal potential is more positive than the resting membrane potential. This developmental shift from depolarizing to hyperpolarizing GABA is mediated by the K⁺-Cl⁻ cotransporter KCC2.
In Alzheimer's disease, several mechanisms upregulate NKCC1 activity and impair KCC2 function:
Aβ oligomers increase NKCC1 expression and activity
The result is increased neuronal excitability, network dysrhythmia, and heightened seizure susceptibility in AD patients[@tavassoly2021].
Bumetanide's Therapeutic Effect
Bumetanide inhibits NKCC1, reducing intracellular chloride and restoring GABA_A-mediated inhibition:
Normalizes the chloride reversal potential
Enhances GABAergic inhibition
Reduces epileptiform activity
May improve synaptic plasticity and memory[@holper2019]
BBB Penetration Challenge
A key limitation of bumetanide for CNS applications is its poor blood-brain barrier penetration. Standard doses achieve limited CNS concentrations. Strategies being explored include:
High-dose regimens
BBB-penetrating analogues
Focused ultrasound to enhance BBB permeability
Intranasal delivery
Clinical Development
NCT06052163: Phase 2 Trial
A Phase 2 clinical trial (NCT06052163) is evaluating bumetanide in early Alzheimer's disease:
Status: Recruiting
Phase: Phase 2
Intervention: Bumetanide
Target: Early AD patients
Primary outcomes: Cognitive measures, safety
This represents the first systematic evaluation of NKCC1 inhibition in a registrational-quality AD trial.
Preclinical Evidence
Multiple preclinical studies support bumetanide's potential in AD:
Reduced seizure-like activity in APP/PS1 mice
Improved performance in memory tasks
Normalized GABAergic inhibition
Reduced neuroinflammation markers
Rationale for AD
Network Hyperexcitability in AD
AD patients show elevated rates of:
Epileptiform discharges on EEG
Subclinical seizures
Accelerated cognitive decline in patients with seizure activity
[Cell-Type Specific TREM2 Upregulation in DAM Microglia](/hypothesis/h-seaad-51323624) — <span style="color:#81c784;font-weight:600">0.70</span> · Target: TREM2